Elizabeth R. Volkmann, MD, MS
Assistant Professor of Medicine
Director, UCLA Scleroderma Program
Co-Director, UCLA CTD-ILD Program
Division of Rheumatology
Department of Medicine
University of California, Los Angeles
David Geffen School of Medicine
Los Angeles, CA
After completing this activity, the participant should be better able to:
- Assess patient risk factors for progressive SSc-ILD
- Describe recommended monitoring for patients with scleroderma and SSc-ILD
- Develop appropriate, evidence-based treatment plans for patients who have SSc-ILD
- Summarize data on emerging agents for the treatment of SSc-ILD
This activity is provided by Paradigm Medical Communications, LLC.
This activity is held in collaboration with the Interstitial Lung Disease Program at the University of Arizona and the Pulmonary Fibrosis Foundation.